secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010526
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut
-----------------------------------------------------------------------

- Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.
- Net income $1.0M ($0.01 basic EPS) vs net loss $4.9M ($0.16 loss) in Q1 2024.
- Partnered with Windtree to reduce PHEXXI manufacturing cost by 55-60%; Evofem bears no tech transfer costs.
- Received $1.5M in April from sale of notes/warrants to Aditxt under merger agreement.
- Cash and restricted cash $1.1M at March 31, 2025; new U.S. patent for SOLOSEC extends to 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/0001641172-25-010526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer